EMEA-000980-PIP01-10-M07

Table of contents

Key facts

Invented name
Adcetris
Active substance
Brentuximab vedotin
Therapeutic area
Oncology
Decision number
P/0013/2021
PIP number
EMEA-000980-PIP01-10-M07
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of anaplastic large cell lymphoma
  • Treatment of Hodgkin lymphoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Takeda Pharma A/S

Tel.  +45(0) 46771111
E-mail: paediatrics@tgrd.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating